Skip to main content
. 2020 Aug 7;12(8):2216. doi: 10.3390/cancers12082216

Table 1.

Spliceosomal mutations in MPN and AML post-MPN patients.

Gene Mutation Frequency (n/N) References
PMF SMF ET PV AML Post MPN
SRSF2 12.2% (351/2876)
Pre-MF: 8.5% (25/294)
2.6% (12/461) 1.5% (31/2132) 1.8% (22/1244) 17% (25/147) [24,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61]
SF3B1 7.7% (135/1751) 6.9% (8/116) 2.8% (62/2207) 1.4% (14/1027) 8.1% (13/161) [45,46,47,48,49,50,51,53,55,56,57,58,59,60,61,62,63,64]
U2AF1 13.8% (200/1448) 4.9% (5/102) 1.1% (23/2132) 0.3% (3/969) 9.5% (14/147) [46,47,48,49,50,53,55,56,57,58,59,60,61]
ZRSR2 5.8% (52/891) 6.9% (7/102) 0.7% (11/1590) 1.3% (7/535) 1.1% (1/91) [46,47,48,55,56,57,58,59,61]
PRPF8 2.1% (2/94) 1.6% (1/64) 2.9% (1/35) 0% (0/8) 5.3% (5/94) [48,50,59]